Now Trump is targeting the pharmaceutical industry
US President Donald Trump wants to reduce the high drug prices in the United States-and primarily targets Europe. « We subsidize the health care of others, » said the Republican in the White House when signing a decrees that will make prescription medication in the USA significantly cheaper in the future. To achieve this, Trump puts pressure on both pharmaceutical companies and foreign governments.
Trump wants to take action against the high medicinal prices with the system of the « Most Favored Nation » (MFN). The idea is to link the reimbursement prices for medication to the lowest price of wealthy comparison countries in order to reduce drug costs in the USA. According to analysis of Simon-Kucher, the MFN model would lead to a severe drop in sales with 53 leading and leading, patent-protected brand preparations. The proceeds of these medication in the United States would decrease by 37 percent globally by 64 percent and globally.
However, Trump emphasizes that his main criticism is less directed against the manufacturers than against other countries. American patients have co -financed the health systems of other countries – including the « Socialist Health System », for example in Germany, for example. In this context, he called the European Union particularly persistent and accused her of behaving more difficult in negotiations than China.
With regard to the measures now announced, Trump said about the EU: « If you want to drive games, you no longer have to sell cars to the USA. »
Whether his measures actually have an effect is open – especially since political and legal resistance can be expected. Trump had already tried to tackle the high prices during his first term, but had failed at the time.
